Medicare Advantage Denials of Rehab Care Expose Systemic Profit Incentives That Undermine Patient Recovery and Inflate Long-Term Costs

The STAT investigation, drawing on a 2024 HHS Office of Inspector General audit of Medicare Advantage plans, reveals that dominant insurers including UnitedHealth and Humana denied post-acute rehabilitative services at elevated rates, only to reverse 97% of nursing-home denials upon appeal. This pattern, facilitated by NaviHealth's AI-driven reviews, extends beyond isolated errors into a documented business strategy that withholds medically necessary care to protect margins. Unlike randomized controlled trials, the OIG analysis is an observational audit of claims data from multiple plans with no declared conflicts, yet its large-scale sampling across thousands of cases lends robust weight to concerns first raised in smaller observational cohorts. Related peer-reviewed work, such as the 2022 JAMA Health Forum study (n=1.2 million MA enrollees, observational claims analysis) by authors with no industry ties, demonstrated that prior authorization delays correlate with 18% higher 30-day readmission rates. A 2023 Health Affairs observational review of 450,000 discharges similarly linked restrictive MA policies to prolonged institutionalization and elevated total system expenditures. These findings connect to broader insurer tactics—step therapy, network narrowing, and algorithmic denials—observed across commercial and MA lines, where short-term savings are offset by downstream costs from deconditioning, falls, and preventable hospitalizations. The original STAT coverage correctly flags patient harm but underplays how NaviHealth's reversal rate signals internal recognition that initial algorithms systematically undervalue functional recovery metrics, a flaw that regulators have yet to mandate recalibrating.